Fredun Pharmaceuticals Ltd — Important, 25-02-2026: Company Update

Fredun Pharmaceuticals has received a credit rating upgrade from Infomerics for its bank facilities totaling ₹156.17 Cr. The long-term rating for facilities, including ₹143.17 Cr, was upgraded to IVR BBB+ (Stable) from IVR BBB (Stable), with short-term ratings reaffirmed at IVR A2. This upgrade reflects improved operational performance, a stronger financial profile, and disciplined capital management. It enhances safety regarding financial obligations, strengthens banking confidence, and improves financial flexibility for the company's expansion initiatives across international markets. For FY25, the company reported revenues of ₹456 Cr, EBITDA of ₹55 Cr, and PAT of ₹21 Cr.